Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment

References

• Bray GA. Evaluation of obesity. Who are the obese? Postgrad Med. 2003;114(6):19–27, 38. doi:10.3810/pgm.2003.12.1544
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021;22(21):11629. PMID: 34769060. doi:10.3390/ijms222111629
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Cuevas J, Sandoval-Rodriguez A, Meza-Rios A, et al. Molecular mechanisms of obesity-linked cardiac dysfunction: an up-date on current knowledge. Cells. 2021;10(3):629. PMID: 33809061. doi:10.3390/cells10030629
   PubMed Web of Science ®Google Scholar
• Boccatonda A, Andreetto L, D’Ardes D, et al. From NAFLD to MAFLD: definition, pathophysiological basis and cardiovascular implications. Biomedicines. 2023;11(3):883. doi:10.3390/biomedicines11030883
   PubMed Web of Science ®Google Scholar
• Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. World Health Organ Tech Rep Ser. 1995;854:1–452.
   PubMed Web of Science ®Google Scholar
• Li Z, Daniel S, Fujioka K, et al. Obesity among Asian American people in the United States: a review. Obesity. 2023;31(2):316–328. doi:10.1002/oby.23639
   PubMed Web of Science ®Google Scholar
• Mayoral L-C, Andrade G, Mayoral E-C, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020;151(1):11–21. doi:10.4103/ijmr.IJMR_1768_17
   PubMed Web of Science ®Google Scholar
• Blüher M, Aras M, Aronne LJ, et al. New insights into the treatment of obesity. Diabetes Obes Metab. 2023;25(8):2058–2072. PMID: 37055715. doi:10.1111/dom.15077
   PubMed Web of Science ®Google Scholar
• Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196. PMID: 32832560. doi:10.1155/2020/3920196
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF DIABETES ATLAS −9th EDITION; April, 2020.
   Google Scholar
• Strey CBM, de Carli LA, Pioner SR, et al. Impact of diabetes mellitus and insulin on nonalcoholic fatty liver disease in the morbidly obese. Ann Hepatol. 2018;17(4):585–591. doi:10.5604/01.3001.0012.0922
   PubMed Web of Science ®Google Scholar
• En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138–2148. PMID: 37491159. doi:10.1136/gutjnl-2023-330110
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919. doi:10.1007/s12072-020-10094-2
   PubMed Web of Science ®Google Scholar
• Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023;101133:101133. doi:10.1016/j.aohep.2023.101133
   Google Scholar
• Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–651. doi:10.1038/s41575-022-00635-5
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Targher G. Concordance of MAFLD and NAFLD diagnostic criteria in “real-world” data. Liver Int. 2020;40:2879–2880. doi:10.1111/liv.14623
   PubMed Web of Science ®Google Scholar
• Ayada I, van Kleef LA, Alferink LJM, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: focusing on the non‐overlap groups. Liver Int. 2021;42(2):277–287. doi:10.1111/liv.15139
   Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. PMID: 30902670. doi:10.1016/S2468-1253(19)30039-1
   PubMed Web of Science ®Google Scholar
• Liu J, Mu C, Li K, Luo H, Liu Y, Li Z. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese children and adolescents: systematic review and meta-analysis. Int J Public Health. 2021;66:1604371. PMID: 34690666. doi:10.3389/ijph.2021.1604371
   PubMed Web of Science ®Google Scholar
• Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573–e582. PMID: 33618024. doi:10.1016/j.cgh.2021.02.030
   PubMed Web of Science ®Google Scholar
• Wu X, Cheung CKY, Ye D, et al. Serum thrombospondin-2 levels are closely associated with the severity of metabolic syndrome and metabolic associated fatty liver disease. J Clin Endocrinol Metab. 2022;107(8):e3230–e3240. PMID: 35532410. doi:10.1210/clinem/dgac292
   PubMed Web of Science ®Google Scholar
• Moreno-Vedia J, Girona J, Ibarretxe D, Masana L, Rodríguez-Calvo R. Unveiling the role of the fatty acid binding protein 4 in the metabolic-associated fatty liver disease. Biomedicines. 2022;10(1):197. PMID: 35052876. doi:10.3390/biomedicines10010197
   PubMed Web of Science ®Google Scholar
• Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018–3030. PMID: 32997882. doi:10.1111/liv.14675
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41(6):1290–1293. PMID: 33590934. doi:10.1111/liv.14828
   PubMed Web of Science ®Google Scholar
• Tsutsumi T, Nakano D, Hashida R, et al. The inter-organ crosstalk reveals an inevitable link between MAFLD and extrahepatic diseases. Nutrients. 2023;15(5):1123. doi:10.3390/nu15051123
   PubMed Web of Science ®Google Scholar
• Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17(1):40–52. doi:10.1038/s41575-019-0212-0
   PubMed Web of Science ®Google Scholar
• Di Renzo L, Sarlo F, Petramala L, et al. Association between −308 G/A TNF- α polymorphism and appendicular skeletal muscle mass index as a marker of sarcopenia in normal weight obese syndrome. Dis Markers. 2013;35(6):615–623. doi:10.1155/2013/983424
   PubMedGoogle Scholar
• Jia A, Xu S, Xing Y, et al. Prevalence and cardiometabolic risks of normal weight obesity in Chinese population: a nationwide study. Nutr Metab Cardiovasc Dis. 2018;28(10):1045–1053. doi:10.1016/j.numecd.2018.06.015
   PubMed Web of Science ®Google Scholar
• Lonardo A, Mantovani A, Lugari S, et al. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19(4):359–366. doi:10.1016/j.aohep.2020.03.001
   PubMed Web of Science ®Google Scholar
• Di Renzo L, Galvano F, Orlandi C, et al. Oxidative stress in normal-weight obese syndrome. Obesity. 2010;18(11):2125–2130. doi:10.1038/oby.2010.50
   PubMed Web of Science ®Google Scholar
• Di Renzo L, Del Gobbo V, Bigioni M, Premrov MG, Cianci R, De Lorenzo A. Body composition analyses in normal weight obese women. Eur Rev Med Pharmacol Sci. 2006;10(4):191–196.
   PubMedGoogle Scholar
• Mathew H, Farr OM, Mantzoros CS. Metabolic health and weight: understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism. 2016;65(1):73–80. doi:10.1016/j.metabol.2015.10.019
   PubMed Web of Science ®Google Scholar
• Højland Ipsen D, Tveden-Nyborg P, Lykkesfeldt J. Normal weight dyslipidemia: is it all about the liver? Obesity. 2016;24(3):556–567. doi:10.1002/oby.21443
   PubMed Web of Science ®Google Scholar
• Mannisto S, Harald K, Kontto J, et al. Dietary and lifestyle characteristics associated with normal-weight obesity: the National FINRISK 2007 Study. Br J Nutr. 2014;111(5):887–894. doi:10.1017/S0007114513002742
   PubMed Web of Science ®Google Scholar
• Ruderman N, Chisholm D, Pi-Sunyer X, et al. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47(5):699–713. doi:10.2337/diabetes.47.5.699
   PubMed Web of Science ®Google Scholar
• De Lorenzo A, Del Gobbo V, Premrov MG, et al. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr. 2007;85(1):40–45. doi:10.1093/ajcn/85.1.40
   PubMed Web of Science ®Google Scholar
• Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939–949. doi:10.1161/01.RES.0000163635.62927.34
   PubMed Web of Science ®Google Scholar
• Lee S-H, Han K, Yang HK, et al. A novel criterion for identifying metabolically obese but normal weight individuals using the product of triglycerides and glucose. Nutr Diabetes. 2015;5(4):e149. doi:10.1038/nutd.2014.46
   PubMed Web of Science ®Google Scholar
• Brandao I, Martins MJ, Monteiro R. Metabolically healthy obesity-heterogeneity in definitions and unconventional factors. Metabolites. 2020;10(2):48. doi:10.3390/metabo10020048
   PubMed Web of Science ®Google Scholar
• Shaharyar S, Roberson LL, Jamal O, et al. Obesity and metabolic phenotypes (metabolically healthy and unhealthy variants) are significantly associated with prevalence of elevated C-reactive protein and hepatic steatosis in a large healthy Brazilian population. J Obes. 2015;2015:178526. doi:10.1155/2015/178526
   PubMedGoogle Scholar
• Iacobini C, Pugliese G, Blasetti Fantauzzi C, et al. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2019;92:51–60. doi:10.1016/j.metabol.2018.11.009
   PubMed Web of Science ®Google Scholar
• Munoz-Garach A, Cornejo-Pareja I, Tinahones FJ. Does metabolically healthy obesity exist? Nutrients. 2016;8(6):320. doi:10.3390/nu8060320
   PubMed Web of Science ®Google Scholar
• Lin H, Zhang L, Zheng R, et al. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: a PRISMA-compliant article. Medicine (Baltimore). 2017;96(47):e8838. doi:10.1097/MD.0000000000008838
   PubMed Web of Science ®Google Scholar
• Perreault M, Zulyniak MA, Badoud F, et al. A distinct fatty acid profile underlies the reduced inflammatory state of metabolically healthy obese individuals. PLoS One. 2014;9(2):e88539. doi:10.1371/journal.pone.0088539
   PubMed Web of Science ®Google Scholar
• Ferrer R, Pardina E, Rossell J, et al. Morbidly “Healthy” obese are not metabolically healthy but less metabolically imbalanced than those with type 2 diabetes or dyslipidemia. Obes Surg. 2015;25(8):1380–1391. doi:10.1007/s11695-014-1528-z
   PubMed Web of Science ®Google Scholar
• Doumatey AP, Zhou J, Zhou M, et al. pro-inflammatory and lipid biomarkers mediate metabolically healthy obesity: a proteomics study. Obesity. 2016;24(6):1257–1265. doi:10.1002/oby.21482
   PubMed Web of Science ®Google Scholar
• Tanriover C, Copur S, Gaipov A, et al. Metabolically healthy obesity: misleading phrase or healthy phenotype? Eur J Intern Med. 2023;111:5–20. doi:10.1016/j.ejim.2023.02.025
   PubMed Web of Science ®Google Scholar
• De Lorenzo A, Soldati L, Sarlo F, et al. New obesity classification criteria as a tool for bariatric surgery indication. World J Gastroenterol. 2016;22(2):681–703. doi:10.3748/wjg.v22.i2.681
   PubMed Web of Science ®Google Scholar
• Dobson R, Burgess MI, Sprung VS, et al. Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int J Obes. 2016;40(1):153–161. doi:10.1038/ijo.2015.151
   PubMed Web of Science ®Google Scholar
• Marques-Vidal P, Bochud M, Bastardot F, et al. Association between inflammatory and obesity markers in a Swiss population-based sample (CoLaus Study). Obes Facts. 2012;5(5):734–744. doi:10.1159/000345045
   PubMed Web of Science ®Google Scholar
• Mamtani M, Kulkarni H, Dyer TD, et al. Genome- and epigenome-wide association study of hypertriglyceridemic waist in Mexican American families. Clin Epigenetics. 2016;8(1):6. doi:10.1186/s13148-016-0173-x
   PubMedGoogle Scholar
• Tyrovolas S, Koyanagi A, Olaya B, et al. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. J Cachexia Sarcopenia Muscle. 2016;7(3):312–321. doi:10.1002/jcsm.12076
   PubMed Web of Science ®Google Scholar
• Abellan van Kan G, Houles M, Vellas B. Identifying sarcopenia. Curr Opin Clin Nutr Metab Care. 2012;15(5):436–441. doi:10.1097/MCO.0b013e328356bbf4
   PubMed Web of Science ®Google Scholar
• Perna S, Spadaccini D, Rondanelli M. Sarcopenic obesity: time to target the phenotypes. J Cachexia Sarcopenia Muscle. 2019;10(3):710–711. doi:10.1002/jcsm.12425
   PubMed Web of Science ®Google Scholar
• Kim JH, Cho JJ, Park YS. Relationship between sarcopenic obesity and cardiovascular disease risk as estimated by the Framingham risk score. J Korean Med Sci. 2015;30(3):264–271. doi:10.3346/jkms.2015.30.3.264
   PubMed Web of Science ®Google Scholar
• Yang CW, Li CI, Li TC, et al. Association of sarcopenic obesity with higher serum high-sensitivity C-reactive protein levels in Chinese older males--a community-based study (Taichung Community Health Study-Elderly, TCHS-E) [published correction appears in PLoS One. 2015;10(8):e0136069]. PLoS One. 2015;10(7):e0132908. PMID: 26177029. doi:10.1371/journal.pone.0132908
   PubMed Web of Science ®Google Scholar
• Perna S, Spadaccini D, Nichetti M, Avanzato I, Faliva MA, Rondanelli M. Osteosarcopenic visceral obesity and osteosarcopenic subcutaneous obesity, two new phenotypes of sarcopenia: prevalence, metabolic profile, and risk factors. J Aging Res. 2018;2018:6147426. PMID: 29862078. doi:10.1155/2018/6147426
   PubMedGoogle Scholar
• Shimabukuro M. Leptin resistance and lipolysis of white adipose tissue: an implication to ectopic fat disposition and its consequences. J Atheroscler Thromb. 2017;24(11):1088–1089. doi:10.5551/jat.ED083
   PubMed Web of Science ®Google Scholar
• Fan X, Yuan W, Huang W, et al. Recent progress in leptin signaling from a structural perspective and its implications for diseases. Biochimie. 2023;212:60–75. doi:10.1016/j.biochi.2023.04.011
   PubMed Web of Science ®Google Scholar
• Haskins IN, Chang J, Nor Hanipah Z, et al. Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease? Surg Obes Relat Dis. 2018;14(3):342–346. doi:10.1016/j.soard.2017.11.032
   PubMed Web of Science ®Google Scholar
• Sung KC, Cha S-C, Sung J-W, et al. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutr Metab Cardiovasc Dis. 2014;24(3):256–262. doi:10.1016/j.numecd.2013.07.005
   PubMed Web of Science ®Google Scholar
• Lonardo A, Bellentani S, Argo CK, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006. doi:10.1016/j.dld.2015.08.004
   PubMedGoogle Scholar
• Rinaldi L, Nascimbeni F, Giordano M, et al. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol. 2017;23(8):1458–1468. doi:10.3748/wjg.v23.i8.1458
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352. doi:10.1016/j.jhep.2017.09.021
   PubMed Web of Science ®Google Scholar
• Badmus OO, Hinds TD, Stec DE. Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease [published online ahead of print, 2023 May 16]. Curr Hypertens Rep. 2023. doi:10.1007/s11906-023-01242-8
   PubMed Web of Science ®Google Scholar
• Foster M, Pagliassotti M. Metabolic alterations following visceral fat removal and expansion: beyond anatomic location. Adipocyte. 2012;1(4):192–199. PMID: 23700533. doi:10.4161/adip.21756
   PubMedGoogle Scholar
• Hernández-Conde M, Llop E, Carrillo C, et al. Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26(42):6658–6668. PMID: 33268953. doi:10.3748/wjg.v26.i42.6658
   PubMed Web of Science ®Google Scholar
• Drozdz K, Nabrdalik K, Hajzler W, et al. Metabolic-Associated Fatty Liver Disease (MAFLD), diabetes, and cardiovascular disease: associations with fructose metabolism and gut microbiota. Nutrients. 2021;14(1):103. doi:10.3390/nu14010103
   PubMed Web of Science ®Google Scholar
• Ma J, Fox CS, Jacques PF, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol. 2015;63(2):462–469. doi:10.1016/j.jhep.2015.03.032
   PubMed Web of Science ®Google Scholar
• Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009;58(9):1281–1288. doi:10.1136/gut.2008.151977
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: evolving paradigms. World J Gastroenterol. 2017;23(36):6571–6592. doi:10.3748/wjg.v23.i36.6571
   PubMed Web of Science ®Google Scholar
• Stender S, Kozlitina J, Nordestgaard BG, et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017;49(6):842–847. doi:10.1038/ng.3855
   PubMed Web of Science ®Google Scholar
• Musio A, Perazza F, Leoni L, et al. Osteosarcopenia in NAFLD/MAFLD: an underappreciated clinical problem in chronic liver disease. Int J Mol Sci. 2023;24(8). doi:10.3390/ijms24087517
   PubMed Web of Science ®Google Scholar
• Chun HS, Lee M, Lee HA, et al. Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(9):2298–2307.e18. doi:10.1016/j.cgh.2022.11.031
   PubMed Web of Science ®Google Scholar
• Choe EY, Lee Y-H, Choi YJ, et al. Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. J Gastroenterol Hepatol. 2018;33(5):1082–1091. doi:10.1111/jgh.14011
   PubMed Web of Science ®Google Scholar
• Shi Y-X, Chen X-Y, Qiu H-N, et al. Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity. Scand J Gastroenterol. 2021;56(3):312–320. doi:10.1080/00365521.2021.1879244
   PubMed Web of Science ®Google Scholar
• Gan D, Wang L, Jia M, et al. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease. Clin Nutr. 2020;39(4):1124–1130. doi:10.1016/j.clnu.2019.04.023
   PubMed Web of Science ®Google Scholar
• Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752. doi:10.1016/S2468-1253(20)30077-7
   PubMed Web of Science ®Google Scholar
• Ito T, Ishigami M, Zou B, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. Hepatol Int. 2021;15(2):366–379. doi:10.1007/s12072-021-10143-4
   PubMed Web of Science ®Google Scholar
• Leung JC, Loong TC-W, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65(1):54–64. doi:10.1002/hep.28697
   PubMed Web of Science ®Google Scholar
• Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol. 2011;54(6):1244–1249. doi:10.1016/j.jhep.2010.09.037
   PubMed Web of Science ®Google Scholar
• Weinberg EM, Trinh HN, Firpi RJ, et al. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases. Clin Gastroenterol Hepatol. 2021;19(5):996–1008.e6. doi:10.1016/j.cgh.2020.06.066
   PubMed Web of Science ®Google Scholar
• Tang A, Ng CH, Phang PH, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD - a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1750–1760.e12. doi:10.1016/j.cgh.2022.06.029
   PubMed Web of Science ®Google Scholar
• Xie X, Guo B, Xiao X, et al. Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study. BMC Public Health. 2022;22(1):118. doi:10.1186/s12889-021-12486-x
   PubMed Web of Science ®Google Scholar
• Amani R, Parohan M, Jomehzadeh N, et al. Dietary and biochemical characteristics associated with normal-weight obesity. Int J Vitam Nutr Res. 2019;89(5–6):331–336. doi:10.1024/0300-9831/a000477
   PubMed Web of Science ®Google Scholar
• Enjoji M, Yasutake K, Kohjima M, et al. Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. Int J Hepatol. 2012;2012:925807. doi:10.1155/2012/925807
   PubMedGoogle Scholar
• Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: a Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology. 2020;71(4):1213–1227. doi:10.1002/hep.30908
   PubMed Web of Science ®Google Scholar
• Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518(7538):187–196. doi:10.1038/nature14132
   PubMed Web of Science ®Google Scholar
• Fehlert E, Wagner R, Ketterer C, et al. Genetic determination of body fat distribution and the attributive influence on metabolism. Obesity. 2017;25(7):1277–1283. doi:10.1002/oby.21874
   PubMed Web of Science ®Google Scholar
• Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17–26. doi:10.1038/ng.3714
   PubMed Web of Science ®Google Scholar
• Wei JL, Leung JC-F, Loong TC-W, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110(9):1306–14; quiz 1315. doi:10.1038/ajg.2015.235
   PubMed Web of Science ®Google Scholar
• Fracanzani AL, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017;15(10):1604–1611.e1. doi:10.1016/j.cgh.2017.04.045
   PubMed Web of Science ®Google Scholar
• Eslam M, Mangia A, Berg T, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64(1):34–46. doi:10.1002/hep.28475
   PubMed Web of Science ®Google Scholar
• Meroni M, Longo M, Lombardi R, et al. Low Lipoprotein(a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2022;6(3):535–549. doi:10.1002/hep4.1830
   PubMed Web of Science ®Google Scholar
• Petta S, Valenti L, Tuttolomondo A, et al. Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology. 2017;66(6):1885–1893. doi:10.1002/hep.29395
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Bjorkstrom K, Stål P, Hultcrantz R, et al. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(9):1461–1468. doi:10.1016/j.cgh.2017.04.040
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang Y, Graham S, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol. 2020;73(2):263–276. doi:10.1016/j.jhep.2020.03.006
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283(4):356–370. doi:10.1111/joim.12719
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109–1123. doi:10.1016/j.metabol.2016.05.003
   PubMed Web of Science ®Google Scholar
• Haigh L, Kirk C, El Gendy K, et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Clin Nutr. 2022;41(9):1913–1931. doi:10.1016/j.clnu.2022.06.037
   PubMed Web of Science ®Google Scholar
• Gepner Y, Shelef I, Komy O, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019;71(2):379–388. doi:10.1016/j.jhep.2019.04.013
   PubMed Web of Science ®Google Scholar
• Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):475–494. doi:10.1016/j.jhep.2013.02.012
   Web of Science ®Google Scholar
• Riebe D, Franklin BA, Thompson PD, et al. Updating ACSM’s recommendations for exercise preparticipation health screening. Med Sci Sports Exerc. 2015;47(11):2473–2479. doi:10.1249/MSS.0000000000000664
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690. doi:10.1016/S0140-6736(15)00803-X
   PubMed Web of Science ®Google Scholar
• Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–1124. doi:10.1056/NEJMoa2028395
   PubMed Web of Science ®Google Scholar
• Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49(1):80–86. doi:10.1002/hep.22575
   PubMed Web of Science ®Google Scholar
• Feng X, Lin Y, Zhuo S, et al. Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: a randomized controlled trial. Am J Clin Nutr. 2023;117(4):691–700. doi:10.1016/j.ajcnut.2023.02.008
   PubMed Web of Science ®Google Scholar
• Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2018;9(1):90–96. doi:10.3892/br.2018.1100
   PubMed Web of Science ®Google Scholar
• Gaur S, Levy S, Mathus-Vliegen L, et al. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc. 2015;81(6):1330–1336. doi:10.1016/j.gie.2015.01.054
   PubMed Web of Science ®Google Scholar
• Bazerbachi F, Haffar S, Sawas T, et al. Fluid-filled versus gas-filled intragastric balloons as obesity interventions: a network meta-analysis of randomized trials. Obes Surg. 2018;28(9):2617–2625. doi:10.1007/s11695-018-3227-7
   PubMed Web of Science ®Google Scholar
• Popov VB, Thompson CC, Kumar N, et al. Effect of intragastric balloons on liver enzymes: a systematic review and meta-analysis. Dig Dis Sci. 2016;61(9):2477–2487. doi:10.1007/s10620-016-4178-2
   PubMed Web of Science ®Google Scholar
• Chandan S, Mohan BP, Khan SR, et al. Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a comprehensive review and meta-analysis. Obes Surg. 2021;31(3):1271–1279. doi:10.1007/s11695-020-05084-0
   PubMed Web of Science ®Google Scholar
• Lopez-Nava G, Galvão MP, Bautista-Castaño I, et al. Endoscopic Sleeve gastroplasty: how I do it? Obes Surg. 2015;25(8):1534–1538. doi:10.1007/s11695-015-1714-7
   PubMed Web of Science ®Google Scholar
• Hajifathalian K, Mehta A, Ang B, et al. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointest Endosc. 2021;93(5):1110–1118. doi:10.1016/j.gie.2020.08.023
   PubMed Web of Science ®Google Scholar
• van Baar A, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69(2):295–303. doi:10.1136/gutjnl-2019-318349
   PubMed Web of Science ®Google Scholar
• de Oliveira G, de Moura DTH, Funari MP, et al. Metabolic effects of endoscopic duodenal mucosal resurfacing: a systematic review and meta-analysis. Obes Surg. 2021;31(3):1304–1312. doi:10.1007/s11695-020-05170-3
   PubMed Web of Science ®Google Scholar
• Benaiges D, Más-Lorenzo A, Goday A, et al. Laparoscopic sleeve gastrectomy: more than a restrictive bariatric surgery procedure? World J Gastroenterol. 2015;21(41):11804–11814. doi:10.3748/wjg.v21.i41.11804
   PubMed Web of Science ®Google Scholar
• Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. Surg Obes Relat Dis. 2019;15(12):2123–2130. doi:10.1016/j.soard.2019.09.060
   PubMed Web of Science ®Google Scholar
• Salman MA, Salman AA, Abdelsalam A, et al. Laparoscopic sleeve gastrectomy on the horizon as a promising treatment modality for NAFLD. Obes Surg. 2020;30(1):87–95. doi:10.1007/s11695-019-04118-6
   PubMed Web of Science ®Google Scholar
• Bjorklund P, Laurenius A, Een E, et al. Is the Roux limb a determinant for meal size after gastric bypass surgery? Obes Surg. 2010;20(10):1408–1414. doi:10.1007/s11695-010-0192-1
   PubMed Web of Science ®Google Scholar
• Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol. 2023;29(suppl):S5–S16. doi:10.3350/cmh.2022.0424
   PubMedGoogle Scholar
• Valenzuela PL, Carrera-Bastos P, Castillo-García A, Lieberman DE, Santos-Lozano A, Lucia A. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol. 2023;20(7):475–494. doi:10.1038/s41569-023-00847-5
   PubMed Web of Science ®Google Scholar
• Li C, Ford ES, Zhao G, et al. Estimates of body composition with dual-energy X-ray absorptiometry in adults. Am J Clin Nutr. 2009;90(6):1457–1465. doi:10.3945/ajcn.2009.28141
   PubMed Web of Science ®Google Scholar
• Chackrewarthy S, Gunasekera D, Pathmeswaren A, et al. A comparison between revised NCEP ATP III and IDF definitions in diagnosing metabolic syndrome in an urban Sri Lankan population: the Ragama Health Study. ISRN Endocrinol. 2013;2013:320176. doi:10.1155/2013/320176
   PubMedGoogle Scholar
• Oliveros E, Somers VK, Sochor O, et al. The concept of normal weight obesity. Prog Cardiovasc Dis. 2014;56(4):426–433. doi:10.1016/j.pcad.2013.10.003
   PubMed Web of Science ®Google Scholar
• Madeira FB, Silva AA, Veloso HF, et al. Normal weight obesity is associated with metabolic syndrome and insulin resistance in young adults from a middle-income country. PLoS One. 2013;8(3):e60673. doi:10.1371/journal.pone.0060673
   PubMed Web of Science ®Google Scholar
• Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. Int J Endocrinol. 2013;2013:204164. doi:10.1155/2013/204164
   PubMed Web of Science ®Google Scholar
• Kang S, Kyung C, Park JS, et al. Subclinical vascular inflammation in subjects with normal weight obesity and its association with body fat: an 18 F-FDG-PET/CT study. Cardiovasc Diabetol. 2014;13:70. doi:10.1186/1475-2840-13-70
   PubMed Web of Science ®Google Scholar
• April-Sanders AK, Rodriguez CJ. Metabolically healthy obesity redefined. JAMA Netw Open. 2021;4(5):e218860. doi:10.1001/jamanetworkopen.2021.8860
   PubMed Web of Science ®Google Scholar
• Bradshaw PT, Monda KL, Stevens J. Metabolic syndrome in healthy obese, overweight, and normal weight individuals: the atherosclerosis risk in communities study. Obesity. 2013;21(1):203–209. doi:10.1002/oby.20248
   PubMed Web of Science ®Google Scholar
• Hoddy KK, Axelrod CL, Mey JT, et al. Insulin resistance persists despite a metabolically healthy obesity phenotype. Obesity. 2022;30(1):39–44. PMID: 34816598. doi:10.1002/oby.23312
   PubMed Web of Science ®Google Scholar
• Li X, Ren Y, Chang K, et al. Adipose tissue macrophages as potential targets for obesity and metabolic diseases. Front Immunol. 2023;14:1153915. doi:10.3389/fimmu.2023.1153915
   PubMed Web of Science ®Google Scholar
• Guria S, Hoory A, Das S, et al. Adipose tissue macrophages and their role in obesity-associated insulin resistance: an overview of the complex dynamics at play. Biosci Rep. 2023;43(3). doi:10.1042/BSR20220200
   PubMed Web of Science ®Google Scholar
• Esser N, L’homme L, De Roover A, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia. 2013;56(11):2487–2497. doi:10.1007/s00125-013-3023-9
   PubMed Web of Science ®Google Scholar
• Alalwan TA. Phenotypes of sarcopenic obesity: exploring the effects on peri-muscular fat, the obesity paradox, hormone-related responses and the clinical implications. Geriatrics (Basel). 2020;5(1):8. doi:10.3390/geriatrics5010008
   PubMedGoogle Scholar
• Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513–537. doi:10.1038/s41574-018-0062-9
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kaido T, Okumura S, et al. Preoperative visceral adiposity and muscularity predict poor outcomes after hepatectomy for hepatocellular carcinoma. Liver Cancer. 2019;8(2):92–109. doi:10.1159/000488779
   PubMed Web of Science ®Google Scholar
• Lee SH, Yang HK, Ha H-S, et al. Changes in metabolic health status over time and risk of developing type 2 diabetes: a prospective cohort study. Medicine (Baltimore). 2015;94(40):e1705. doi:10.1097/MD.0000000000001705
   PubMed Web of Science ®Google Scholar
• Hamer M, Bell JA, Sabia S, et al. Stability of metabolically healthy obesity over 8 years: the English Longitudinal Study of Ageing. Eur J Endocrinol. 2015;173(5):703–708. doi:10.1530/EJE-15-0449
   PubMed Web of Science ®Google Scholar
• Bell JA, Hamer M, Sabia S, et al. The natural course of healthy obesity over 20 years. J Am Coll Cardiol. 2015;65(1):101–102. doi:10.1016/j.jacc.2014.09.077
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Kushner RF, Kahan S. Introduction: the State of Obesity in 2017. Med Clin North Am. 2018;102(1):1–11. doi:10.1016/j.mcna.2017.08.003
   PubMed Web of Science ®Google Scholar
• Pang Q, Zhang JY, Song SD, et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol. 2015;21(5):1650–1662. doi:10.3748/wjg.v21.i5.1650
   PubMed Web of Science ®Google Scholar
• Chang Y, Jung H-S, Cho J, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111(8):1133–1140. doi:10.1038/ajg.2016.178
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, dos-Santos-Silva I, Leon DA, et al. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944–953. doi:10.1016/S2213-8587(18)30288-2
   PubMed Web of Science ®Google Scholar
• Argo CK, Stine JG, Henry ZH, et al. Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2018;48(3):290–299. doi:10.1111/apt.14803
   PubMed Web of Science ®Google Scholar
• Zhang S, Du T, Li M, et al. Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. Medicine (Baltimore). 2017;96(12):e6381. doi:10.1097/MD.0000000000006381
   PubMed Web of Science ®Google Scholar
• Liu DJ, Peloso GM, Yu H, et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017;49(12):1758–1766. doi:10.1038/ng.3977
   PubMed Web of Science ®Google Scholar
• Kim Y, Chang Y, Cho YK, et al. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease. Liver Int. 2019;39(10):1884–1894. doi:10.1111/liv.14184
   PubMed Web of Science ®Google Scholar
• Gutierrez-Grobe Y, Juárez-Hernández E, Sánchez-Jiménez BA, et al. Less liver fibrosis in metabolically healthy compared with metabolically unhealthy obese patients with non-alcoholic fatty liver disease. Diabetes Metab. 2017;43(4):332–337. doi:10.1016/j.diabet.2017.02.007
   PubMed Web of Science ®Google Scholar
• Ampuero J, Aller R, Gallego‐Durán R, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48(11–12):1260–1270. doi:10.1111/apt.15015
   PubMed Web of Science ®Google Scholar
• Lee MJ, Kim E-H, Bae S-J, et al. Age-related decrease in skeletal muscle mass is an independent risk factor for incident nonalcoholic fatty liver disease: a 10-year retrospective cohort study. Gut Liver. 2019;13(1):67–76. doi:10.5009/gnl18070
   PubMed Web of Science ®Google Scholar
• Kim G, Lee S-E, Lee Y-B, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology. 2018;68(5):1755–1768. doi:10.1002/hep.30049
   PubMed Web of Science ®Google Scholar
• Hyun Kim K, Kyung Kim B, Yong Park J, et al. Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. Eur J Gastroenterol Hepatol. 2020;32(1):58–65. doi:10.1097/MEG.0000000000001475
   PubMed Web of Science ®Google Scholar
• Chun HS, Kim MN, Lee JS, et al. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle. 2021;12(5):1168–1178. doi:10.1002/jcsm.12754
   PubMed Web of Science ®Google Scholar
• Rigor J, Vasconcelos R, Lopes R, Moreira T, Barata P, Martins-Mendes D. Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease [published online ahead of print, 2022 Mar 28]. Minerva Gastroenterol (Torino). 2022. doi:10.23736/S2724-5985.22.03097-2
   PubMedGoogle Scholar
• Petermann-Rocha F, Gray SR, Forrest E, et al. Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK Biobank participants. J Hepatol. 2022;76(5):1021–1029. doi:10.1016/j.jhep.2022.01.010
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564–568. doi:10.1136/gutjnl-2019-318813
   PubMed Web of Science ®Google Scholar
• Golabi P, Paik JM, Arshad T, et al. Mortality of NAFLD according to the body composition and presence of metabolic abnormalities. Hepatol Commun. 2020;4(8):1136–1148. doi:10.1002/hep4.1534
   PubMed Web of Science ®Google Scholar
• Li C, Guo P, Okekunle AP, et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol. 2019;34(1):256–262. doi:10.1111/jgh.14360
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46(2):85–95. doi:10.1111/apt.14112
   PubMed Web of Science ®Google Scholar
• Zeng J, Yang R-X, Sun C, et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol. 2020;26(15):1792–1804. doi:10.3748/wjg.v26.i15.1792
   PubMed Web of Science ®Google Scholar
• Hagstrom H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2018;2(1):48–57. doi:10.1002/hep4.1124
   PubMed Web of Science ®Google Scholar
• Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022;71(2):382–390. doi:10.1136/gutjnl-2020-322564
   PubMed Web of Science ®Google Scholar
• Wei L, Cheng X, Luo Y, et al. Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: a cohort study. Diabetes Metab. 2021;47(3):101200. doi:10.1016/j.diabet.2020.08.008
   PubMed Web of Science ®Google Scholar
• Zou B, Yeo YH, Nguyen VH, et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med. 2020;288(1):139–151. doi:10.1111/joim.13069
   PubMed Web of Science ®Google Scholar
• Golabi P, Paik J, Fukui N, et al. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes. 2019;37(1):65–72. doi:10.2337/cd18-0026
   PubMedGoogle Scholar
• Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634–642. doi:10.1007/s00125-005-1682-x
   PubMed Web of Science ®Google Scholar
• Denkmayr L, Feldman A, Stechemesser L, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med. 2018;7(12):562. doi:10.3390/jcm7120562
   PubMed Web of Science ®Google Scholar
• Wang Q, You H, Ou X, et al. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hepatol Int. 2019;13(6):766–776. doi:10.1007/s12072-019-09982-z
   PubMed Web of Science ®Google Scholar
• Gujral UP, Vittinghoff E, Mongraw-Chaffin M, et al. Cardiometabolic abnormalities among normal-weight persons from five racial/ethnic groups in the United States: a cross-sectional analysis of two cohort studies. Ann Intern Med. 2017;166(9):628–636. doi:10.7326/M16-1895
   PubMed Web of Science ®Google Scholar
• Tabung FK, Steck SE, Zhang J, et al. Construct validation of the dietary inflammatory index among postmenopausal women. Ann Epidemiol. 2015;25(6):398–405. doi:10.1016/j.annepidem.2015.03.009
   PubMed Web of Science ®Google Scholar
• Ji Y, Yiorkas AM, Frau F, et al. Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension. Diabetes. 2019;68(1):207–219. doi:10.2337/db18-0708
   PubMed Web of Science ®Google Scholar
• Yaghootkar H, Lotta LA, Tyrrell J, et al. Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension, and heart disease. Diabetes. 2016;65(8):2448–2460. doi:10.2337/db15-1671
   PubMed Web of Science ®Google Scholar
• Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268–279. doi:10.1016/j.jhep.2017.09.003
   PubMed Web of Science ®Google Scholar
• Bale G, Vishnubhotla RV, Mitnala S, et al. Whole-exome sequencing identifies a variant in phosphatidylethanolamine N-methyltransferase gene to be associated with lean-nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9(5):561–568. doi:10.1016/j.jceh.2019.02.001
   PubMed Web of Science ®Google Scholar
• Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99–114. doi:10.1038/nrendo.2017.173
   PubMed Web of Science ®Google Scholar
• Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154170. doi:10.1016/j.metabol.2020.154170
   PubMed Web of Science ®Google Scholar
• Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol. 2019;56(4):385–396. doi:10.1007/s00592-018-1266-0
   PubMed Web of Science ®Google Scholar
• Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599–612. doi:10.1038/s41575-021-00448-y
   PubMed Web of Science ®Google Scholar
• Jeeyavudeen MS, Khan SK, Fouda S, et al. Management of metabolic-associated fatty liver disease: the diabetology perspective. World J Gastroenterol. 2023;29(1):126–143. doi:10.3748/wjg.v29.i1.126
   PubMed Web of Science ®Google Scholar
• Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962–969. doi:10.1136/gutjnl-2020-322572
   PubMed Web of Science ®Google Scholar
• Morrison AE, Zaccardi F, Khunti K, et al. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis. Liver Int. 2019;39(3):557–567. doi:10.1111/liv.13994
   PubMed Web of Science ®Google Scholar
• Nasr P, Ignatova S, Kechagias S, et al. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2(2):199–210. doi:10.1002/hep4.1134
   PubMed Web of Science ®Google Scholar
• Nasr P, Fredrikson M, Ekstedt M, et al. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int. 2020;40(5):1069–1078. doi:10.1111/liv.14414
   PubMed Web of Science ®Google Scholar
• Bae JC, Han JM, Cho JH, et al. The persistence of fatty liver has a differential impact on the development of diabetes: the Kangbuk Samsung Health Study. Diabetes Res Clin Pract. 2018;135:1–6. doi:10.1016/j.diabres.2017.10.019
   PubMed Web of Science ®Google Scholar
• Lee J, Cho YK, Kang YM, et al. The impact of NAFLD and waist circumference changes on diabetes development in prediabetes subjects. Sci Rep. 2019;9(1):17258. doi:10.1038/s41598-019-53947-z
   PubMedGoogle Scholar
• Cho HJ, Hwang S, Park JI, et al. Improvement of nonalcoholic fatty liver disease reduces the risk of type 2 diabetes mellitus. Gut Liver. 2019;13(4):440–449. doi:10.5009/gnl18382
   PubMed Web of Science ®Google Scholar
• Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013;98(9):3637–3643. doi:10.1210/jc.2013-1519
   PubMed Web of Science ®Google Scholar
• Zaharia OP, Strassburger K, Strom A, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019;7(9):684–694. doi:10.1016/S2213-8587(19)30187-1
   PubMed Web of Science ®Google Scholar
• Zaharia OP, Strassburger K, Knebel B, et al. Role of patatin-like phospholipase domain-containing 3 gene for hepatic lipid content and insulin resistance in diabetes. Diabetes Care. 2020;43(9):2161–2168. doi:10.2337/dc20-0329
   PubMed Web of Science ®Google Scholar
• Al-Mrabeh A, Zhyzhneuskaya SV, Peters C, et al. Hepatic lipoprotein export and remission of human type 2 diabetes after weight loss. Cell Metab. 2020;31(2):233–249.e4. doi:10.1016/j.cmet.2019.11.018
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–64. doi:10.1016/j.jhep.2014.12.012
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42. doi:10.1038/nrgastro.2016.147
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Wadden TA, Longo DL. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(15):1492. doi:10.1056/NEJMra1514009
   PubMedGoogle Scholar
• Hashem A, Khalouf A, Acosta A. Management of obesity and nonalcoholic fatty liver disease: a literature review. Semin Liver Dis. 2021;41(4):435–447. doi:10.1055/s-0041-1731704
   PubMedGoogle Scholar
• Stefano JT, Duarte SMB, Ribeiro Leite Altikes RG, et al. Non-pharmacological management options for MAFLD: a practical guide. Ther Adv Endocrinol Metab. 2023;14:20420188231160394. doi:10.1177/20420188231160394
   Web of Science ®Google Scholar
• Chai XN, Zhou B-Q, Ning N, et al. Effects of lifestyle intervention on adults with metabolic associated fatty liver disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1081096. doi:10.3389/fendo.2023.1081096
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885–904. doi:10.1007/s00125-011-2446-4
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.e5; quiz e14–5. doi:10.1053/j.gastro.2015.04.005
   Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023. doi:10.1016/j.jacc.2013.11.004
   PubMed Web of Science ®Google Scholar
• Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the United States. Am J Med. 2016;129(8):879.e1–6. doi:10.1016/j.amjmed.2016.02.009
   PubMed Web of Science ®Google Scholar
• Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882. doi:10.1016/j.eclinm.2023.101882
   PubMedGoogle Scholar
• Prikhodko VA, Bezborodkina NN, Okovityi SV. Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates. Biomedicines. 2022;10(2):274. doi:10.3390/biomedicines10020274
   PubMed Web of Science ®Google Scholar
• Sangro P, de la Torre Aláez M, Sangro B, D’Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment [published online ahead of print, 2023 Mar 28]. J Physiol Biochem. 2023. doi:10.1007/s13105-023-00954-4
   Web of Science ®Google Scholar
• Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2022;13:1087260. doi:10.3389/fendo.2022.1087260
   PubMedGoogle Scholar
• Maestri M, Santopaolo F, Pompili M, et al. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: effects of current treatments and future strategies. Front Nutr. 2023;10:1110536. doi:10.3389/fnut.2023.1110536
   PubMed Web of Science ®Google Scholar
• Ali MR, Moustarah F, Kim JJ. American society for metabolic and bariatric surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons. Surg Obes Relat Dis. 2016;12(3):462–467. doi:10.1016/j.soard.2015.12.026
   PubMed Web of Science ®Google Scholar
• NASH News March. 2021—Recognizing NASH patient advocacy. Available from: https://www.globalliver.org/news/2021/nash-news-march. Accessed April 5, 2021
   Google Scholar
• Lazaridis II, Delko T. Bariatric surgery and metabolic dysfunction-associated fatty liver disease: a 2022 update. Praxis. 2023;112(2):97–102. doi:10.1024/1661-8157/a003969
   PubMedGoogle Scholar
• Lassailly G, Caiazzo R, Ntandja-Wandji L-C, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159(4):1290–1301.e5. doi:10.1053/j.gastro.2020.06.006
   PubMed Web of Science ®Google Scholar
• Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–511. doi:10.1016/j.soard.2018.12.002
   PubMed Web of Science ®Google Scholar